Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10320528" target="_blank" >RIV/00216208:11110/15:10320528 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10320528
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1505654" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1505654</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1505654" target="_blank" >10.1056/NEJMoa1505654</a>

Result language
angličtina
Original language name
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Original language description
Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95%confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fat
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)